# Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia

> **NCT02735629** · PHASE2 · UNKNOWN · sponsor: **RespireRx** · enrollment: 18 (actual)

## Conditions studied

- Opiate Induced Respiratory Depression

## Interventions

- **DRUG:** CX1739 - 300 mg
- **DRUG:** CX1739 - 600 mg
- **DRUG:** CX1739 - 900 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02735629
- **Lead sponsor:** RespireRx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03
- **Primary completion:** 2016-08
- **Final completion:** 2016-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2016-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02735629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02735629, "Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02735629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*